Iero PT, et al. - Authors ascertained the effectiveness and safety of an opioid-sparing postsurgical pain management protocol with or without local infiltration of liposomal bupivacaine for full-arch implant surgery in this prospective, randomized, open-label trial. A statistically significant reduction of postsurgical pain and clinically relevant reduction in opioid consumption were experienced by the patients receiving an opioid-sparing postsurgical pain management protocol with liposomal bupivacaine 266 mg. Patients receiving an opioid-sparing postsurgical pain management protocol with or without liposomal bupivacaine demonstrated comparability of the overall incidence of treatment-emergent adverse events.